Following Friday's purchase, this biopharma's weighting in ARKG stood at 1.06%, attributed to the 51,712 shares held by the exchange-traded fund.
The biopharma company has opted to prioritize a pipeline asset that is in Phase 2 study for obesity and is positive about its potential.
